| HOME >> BIOLOGY >> TECHNOLOGY |
Share-based
compensation
expense and
other (1,175) 56 (2,970) (1,404)
Tax expense on
a non-GAAP
basis (4,672)30.9% $(1,435)36.8% $(12,759)32.0% $(5,296)30.6%
The following table reconciles the guidance on a GAAP and non-GAAP
basis for the periods shown below:
THORATEC CORPORATION
Reconciliation of GAAP to Non-GAAP Forward-Looking Guidance
(Unaudited)
(shares in thousands)
Diluted net income per share
reconciliation For the Fiscal Year Ended 2008
From To
Diluted net income per share on a
GAAP basis $0.31 $0.37
Share-based compensation expense 0.16 0.18
Amortization of purchased intangibles 0.21 0.21
Income tax effect of non-GAAP
adjustments (0.14) (0.17)
Diluted net income per share on a
non-GAAP basis $0.54 $0.59
Shares used in calculation of diluted
net income per share --GAAP 63,500 63,500
Shares used in calculation of
diluted net income per share --non-
GAAP (a) 63,500 63,500
(a) Shares used in the per share calculation for reconciling items.
between GAAP and non-GAAP financial measures.
Thoratec is a world leader in therapies to address advanced-stage heart
failure. The company's product lines include the Thoratec(R) VAD and
HeartMate LVAS with nearly 12,000 devices implanted in patients suffering
from heart failure. Additionall
'/>"/>
| SOURCE Thoratec Corporation Copyright©2008 PR Newswire. All rights reserved |